Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05409989 · ClinicalTrials.gov registry record · NA

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

A NA study of Intracranial Aneurysm, sponsored by Microvention-Terumo.

Active
Registry status
NA
Development phase
154
Enrollment target
20
Study locations

NCT05409989: Active NA study of Intracranial Aneurysm, sponsored by Microvention-Terumo.

NCT05409989 is a NA study of Intracranial Aneurysm that is active but no longer recruiting, run by Microvention-Terumo. The registered enrollment target is 154 participants, below the 9,185-participant average among 14 other Intracranial Aneurysm trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05409989, a NA study of Intracranial Aneurysm, is active but no longer recruiting, sponsored by Microvention-Terumo.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
154 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.

Primary Outcome

Major stroke is defined as a new neurological event that persists for \>24 hours and results in a ≥4-point increase in the NIHSS score compared to baseline or compared to any subsequent lower score.

Conditions Studied

Interventions

  • DEVICE FRED™ X™

Study Locations (20)

New York

  • Albany Medical Center - Albany
  • University at Buffalo - Buffalo
  • Northwell Health - Manhasset
  • Mount Sinai - New York
  • Stony Brook University - Stony Brook
  • Montefiore Medical Center - The Bronx

Florida

  • Memorial Healthcare Systems - Hollywood
  • Orlando Health - Orlando

Kentucky

  • Baptist Healthcare System - Louisville
  • Norton Healthcare - Louisville

Massachusetts

  • Massachusetts General Brigham Incorporated - Boston
  • UMass Memorial Health - Worcester

Ohio

  • Ohio State University - Columbus
  • ProMedica Toledo Hospital - Toledo

Hawaii

  • Queen's Medical Center - Honolulu

Iowa

  • University of Iowa - Iowa City

Kansas

  • University of Kansas - Kansas City

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2022-09-20
Est. Completion 2029-11
Phase NA
Microvention-Terumo

9 total trials

What the registry record for NCT05409989 still lists

NCT05409989 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 9,185-participant average among 14 other Intracranial Aneurysm trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Intracranial Aneurysm appearing as the primary indexed condition, and to 1 intervention - of which FRED™ X™ is the first listed.

NCT05409989 names 20 study sites across 11 states, led by New York, Florida, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05409989 about?

NCT05409989 is a clinical study titled "MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study". The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device b...

What is the current status of trial NCT05409989?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 154 participants. The study started on 2022-09-20. Estimated completion is 2029-11.

What conditions does trial NCT05409989 study?

This clinical trial studies the following conditions: Intracranial Aneurysm.

What interventions are being tested in trial NCT05409989?

The interventions under investigation include: FRED™ X™ (DEVICE).

Who is sponsoring clinical trial NCT05409989?

This trial is sponsored by Microvention-Terumo, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05409989 being conducted?

This trial has 20 study locations across Florida, Hawaii, Iowa, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intracranial Aneurysm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05409989's enrollment target sits among peer trials

154 12th of 14 higher than 3 of 14 other Intracranial Aneurysm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Intracranial Aneurysm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04300998 · 154 participants

    Study of CAR-T Therapy in Older Patients

  • NCT04597372 · 154 participants · Phase 2

    Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

  • NCT05294042 · 154 participants · NA

    Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities

  • NCT05512390 · 154 participants · Phase 1

    A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05409989, the US trial registry maintained by the National Library of Medicine. NCT05409989 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.